2026 Q2 Portfolio Activity
In 2026 Q2, Caligan Partners LP maintained a portfolio of 33 distinct positions. The most significant new addition was IMMUNOCORE HLDGS PLC, now representing 2.06% of the total fund value. They heavily accumulated shares in REVOLUTION MEDICINES INC, increasing the position by 757.1%. The fund also reduced its exposure to REVOLUTION MEDICINES INC by 84.8%.
Position History
hover any row below to update
Loading…
Total Positions
33
Quarter
2026 Q2
Top Holding
LQDA (30.5%)
Top 10 Concentration
80.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-33 of 33
Caligan Partners LP Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
LQDA
LIQUIDIA CORPOR...
|
Healthcare | 30.45% | 20.39% |
#1
Prev: #1
|
7.0 |
—
|
no change | no change |
P
S
|
8,118,892 | $647,319,259 | 2022 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 17.28% | 10.70% |
#2
1
Prev: #3
|
7.5 |
—
|
308,987 | 18.7% |
P
S
|
1,961,795 | $367,404,968 | 2025 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ABVX
ABIVAX SA
|
Healthcare | 9.77% | 10.83% |
#3
1
Prev: #2
|
6.9 |
—
|
96,000 | 6.6% |
P
S
|
1,557,924 | $207,608,952 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 5.99% | 7.97% |
#4
Prev: #4
|
4.9 |
—
|
127,917 | 6.2% |
P
S
|
2,188,636 | $127,225,411 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
EXEL
EXELIXIS INC
|
Healthcare | 3.98% | 4.43% |
#5
2
Prev: #7
|
3.1 |
—
|
no change | no change |
P
S
|
1,553,262 | $84,512,985 | 2023 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 3.68% | 3.35% |
#6
3
Prev: #9
|
2.0 |
—
|
91,305 | 3.8% |
P
S
|
2,500,103 | $78,153,220 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 2.75% | 1.62% |
#7
12
Prev: #19
|
4.1 |
—
|
1,528,843 | 93.5% |
P
S
|
3,163,866 | $58,468,244 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 2.53% | 5.39% |
#8
3
Prev: #5
|
1.0 |
—
|
-503,083 | -36.1% |
P
S
|
889,944 | $53,717,020 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ADMA
ADMA BIOLOGICS ...
|
Healthcare | 2.25% | 2.85% |
#9
3
Prev: #12
|
3.4 |
—
|
968,496 | 20.4% |
P
S
|
5,725,007 | $47,918,309 | 2022 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
RVMD
CALL
REVOLUTION MEDI...
|
CALL Option | 2.22% | 1.48% |
#10
10
Prev: #20
|
2.9 |
—
|
22,900 | 10.0% |
P
S
|
251,800 | $47,157,104 | 2025 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
LBRX
LB PHARMACEUTIC...
|
Healthcare | 2.20% | 2.30% |
#11
2
Prev: #13
|
1.9 |
—
|
no change | no change |
P
S
|
1,438,070 | $46,672,562 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IMCR
IMMUNOCORE HLDG...
|
Healthcare | 2.06% | — |
#12
Prev: #—
|
4.3 |
—
|
1,381,317 | — |
NEW
|
1,381,317 | $43,856,815 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 1.90% | — |
#13
Prev: #—
|
4.3 |
—
|
2,193,981 | — |
NEW
|
2,193,981 | $40,303,431 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
VOR
VOR BIOPHARMA I...
|
Healthcare | 1.67% | 2.29% |
#14
Prev: #14
|
1.7 |
—
|
no change | no change |
P
S
|
1,925,066 | $35,440,465 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SABS
SAB BIOTHERAPEU...
|
Healthcare | 1.46% | 2.03% |
#15
Prev: #15
|
1.6 |
—
|
no change | no change |
P
S
|
7,967,207 | $31,072,107 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IVA
INVENTIVA SA
|
Healthcare | 1.45% | 1.84% |
#16
1
Prev: #17
|
3.6 |
—
|
3,188,285 | 64.1% |
P
S
|
8,163,191 | $30,856,862 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AURA
AURA BIOSCIENCE...
|
Healthcare | 1.44% | 0.10% |
#17
10
Prev: #27
|
3.6 |
—
|
4,068,384 | 1769.9% |
P
S
|
4,298,248 | $30,517,561 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TYRA
TYRA BIOSCIENCE...
|
Healthcare | 1.21% | 3.25% |
#18
8
Prev: #10
|
0.5 |
—
|
-469,982 | -36.8% |
P
S
|
806,986 | $25,775,133 | 2025 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IRD
OPUS GENETICS I...
|
Healthcare | 1.17% | 1.84% |
#19
3
Prev: #16
|
1.0 |
—
|
2,056 | 0.0% |
P
S
|
6,077,084 | $24,976,815 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ANIK
ANIKA THERAPEUT...
|
Healthcare | 0.99% | 1.38% |
#20
1
Prev: #21
|
1.4 |
—
|
no change | no change |
P
S
|
1,435,130 | $20,995,952 | 2022 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SGMT
SAGIMET BIOSCIE...
|
Healthcare | 0.91% | — |
#21
Prev: #—
|
3.9 |
—
|
2,500,000 | — |
NEW
|
2,500,000 | $19,325,000 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ARTV
ARTIVA BIOTHERA...
|
Healthcare | 0.79% | — |
#22
Prev: #—
|
3.8 |
—
|
1,736,111 | — |
NEW
|
1,736,111 | $16,840,277 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SNSE
FAETH THERAPEUT...
|
Healthcare | 0.74% | 0.26% |
#23
1
Prev: #24
|
3.3 |
—
|
503,465 | 399.6% |
P
S
|
629,467 | $15,736,675 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 0.52% | 1.69% |
#24
6
Prev: #18
|
0.2 |
—
|
-648,590 | -76.4% |
P
S
|
200,000 | $11,040,000 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
VRCA
VERRICA PHARMAC...
|
Healthcare | 0.27% | 0.33% |
#25
2
Prev: #23
|
1.1 |
—
|
no change | no change |
P
S
|
923,910 | $5,654,329 | 2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AGIO
CALL
AGIOS PHARMACEU...
|
CALL Option | 0.16% | 0.20% |
#26
1
Prev: #25
|
1.1 |
—
|
no change | no change |
P
S
|
90,000 | $3,339,900 | 2022 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ADMA
CALL
ADMA BIOLOGICS ...
|
CALL Option | 0.12% | 0.18% |
#27
1
Prev: #26
|
1.0 |
—
|
no change | no change |
P
S
|
300,000 | $2,511,000 | 2022 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CLRB
CELLECTAR BIOSC...
|
Healthcare | 0.06% | — |
#28
Prev: #—
|
3.5 |
—
|
469,998 | — |
NEW
|
469,998 | $1,306,594 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
XILIO THERAPEUT...
|
|
Unknown | 0.00% | 0.06% |
Sold All 😨
(Was: #28) |
0.0 |
—
|
-112,128 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 0.00% | 1.22% |
Sold All 😨
(Was: #22) |
0.0 |
—
|
-614,962 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 0.00% | 2.95% |
Sold All 😨
(Was: #11) |
0.0 |
—
|
-878,127 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CGON
CALL
CG ONCOLOGY INC
|
CALL Option | 0.00% | 4.05% |
Sold All 😨
(Was: #8) |
0.0 |
—
|
-900,000 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MLYS
MINERALYS THERA...
|
Healthcare | 0.00% | 5.00% |
Sold All 😨
(Was: #6) |
0.0 |
—
|
-2,772,654 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-33 of 33 holdings